Zura Bio to Participate in Guggenheim Biotech Summit

Clinical-stage biotech company to present at upcoming investor conference.

Published on Feb. 5, 2026

Got story updates? Submit your updates here. ›

Zura Bio Limited, a clinical-stage biotechnology company developing novel medicines for autoimmune and inflammatory diseases, announced that its senior leadership team will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The company will also conduct one-on-one investor meetings on the same day.

Why it matters

Zura Bio's participation in the Guggenheim Biotech Summit provides an opportunity for the company to showcase its pipeline of product candidates and engage with potential investors as it continues to advance its clinical programs.

The details

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company's lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis. Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.

  • The Guggenheim Emerging Outlook: Biotech Summit will take place on Wednesday, February 11, 2026.
  • Zura Bio's fireside chat is scheduled for 11:00 AM ET on February 11, 2026.

The players

Zura Bio Limited

A clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases.

Guggenheim Emerging Outlook: Biotech Summit

An investor conference focused on emerging biotechnology companies.

Got photos? Submit your photos here. ›

What they’re saying

“A live webcast of the presentation will be available in the Investors section of the Company's website under News & Events. A replay will remain archived for at least 30 days.”

— Megan K. Weinshank, Head of Corporate Affairs (Business Wire)

What’s next

Investors and other interested parties will be able to access the live webcast of Zura Bio's fireside chat on the company's website, and a replay will be available for at least 30 days following the event.

The takeaway

Zura Bio's participation in the Guggenheim Biotech Summit demonstrates the company's commitment to engaging with the investment community as it continues to advance its pipeline of novel immunology-based therapies for autoimmune and inflammatory diseases.